Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
- PMID: 32982178
- PMCID: PMC7507407
- DOI: 10.2147/DDDT.S272355
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
Abstract
Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development.
Keywords: Astragalus membranaceus; astragaloside IV; cardiomyocytes; cardiovascular diseases; traditional Chinese medicine.
© 2020 Tan et al.
Conflict of interest statement
All authors declare that there are no conflicts of interest in publishing this work in whole or in part and report no conflicts of interest for this work.
Figures


Similar articles
-
Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV.Biomed Pharmacother. 2023 Dec;168:115752. doi: 10.1016/j.biopha.2023.115752. Epub 2023 Oct 22. Biomed Pharmacother. 2023. PMID: 37875045 Review.
-
An updated role of astragaloside IV in heart failure.Biomed Pharmacother. 2020 Jun;126:110012. doi: 10.1016/j.biopha.2020.110012. Epub 2020 Mar 23. Biomed Pharmacother. 2020. PMID: 32213428 Review.
-
Research progress of natural medicine Astragalus mongholicus Bunge in treatment of myocardial fibrosis.J Ethnopharmacol. 2023 Apr 6;305:116128. doi: 10.1016/j.jep.2022.116128. Epub 2023 Jan 6. J Ethnopharmacol. 2023. PMID: 36623754 Review.
-
Research progress of astragaloside IV in the treatment of atopic diseases.Biomed Pharmacother. 2022 Dec;156:113989. doi: 10.1016/j.biopha.2022.113989. Epub 2022 Nov 8. Biomed Pharmacother. 2022. PMID: 36411656 Review.
-
Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.Adv Pharmacol. 2020;87:89-112. doi: 10.1016/bs.apha.2019.08.002. Epub 2019 Dec 18. Adv Pharmacol. 2020. PMID: 32089240 Review.
Cited by
-
Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.Front Endocrinol (Lausanne). 2024 Sep 30;15:1366285. doi: 10.3389/fendo.2024.1366285. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39403576 Free PMC article. Review.
-
Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation.World J Clin Cases. 2022 Oct 6;10(28):10004-10016. doi: 10.12998/wjcc.v10.i28.10004. World J Clin Cases. 2022. PMID: 36246793 Free PMC article. Review.
-
Astragaloside IV Protects against Shear Stress-Induced Glycocalyx Damage and Alleviates Abdominal Aortic Aneurysm by Regulating miR-17-3p/Syndecan-1.Anal Cell Pathol (Amst). 2024 Feb 13;2024:2348336. doi: 10.1155/2024/2348336. eCollection 2024. Anal Cell Pathol (Amst). 2024. PMID: 39290461 Free PMC article.
-
Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites.Front Cell Infect Microbiol. 2022 May 17;12:836150. doi: 10.3389/fcimb.2022.836150. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35656031 Free PMC article.
-
Targeted Mitochondrial Drugs for Treatment of Ischemia-Reperfusion Injury.Curr Drug Targets. 2022;23(16):1526-1536. doi: 10.2174/1389450123666220913121422. Curr Drug Targets. 2022. PMID: 36100990 Review.
References
-
- Cardiovascular diseases (CVDs): health Topics; Updated May 2017. Available from: https://www.who.int/cardiovascular_diseases/en/. Accessed 24June 2020.
-
- WHO library cataloguing-in-publication data: hearts: technical package for cardiovascular disease management in primary health care. Available from: https://www.who.int/cardiovascular_diseases/hearts/Hearts_package.pdf. Accessed September3, 2020.
-
- Liu P, Shan G, Zhang F, Chen JN, Jia TZ. Metabolomics analysis and rapid identification of changes in chemical ingredients in crude and processed Astragali Radix by UPLC-QTOF-MS combined with novel informatics UNIFI platform. Chin J Nat Med. 2018;16(9):714–720. doi:10.1016/S1875-5364(18)30111-0 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials